Colorectal cancer is the third leading cause of cancer death in the United States, with over 50,000 deaths annually1 2. Screening colonoscopy plays a crucial role in reducing mortality by detecting and removing precancerous lesions early1 2. However, patient adherence to colonoscopy screening is often hindered by the unpleasant experience of bowel preparation, which is essential for effective examination3 4. The recent FDA approval of Suflave, a low-volume, sports drink-flavored colonoscopy prep, offers a promising advancement to improve patient tolerance and potentially increase screening rates5 6.
Suflave vs. Traditional Colonoscopy Prep Options
Bowel preparation quality is critical for a successful colonoscopy, as inadequate cleansing can lead to missed lesions and the need for repeat procedures3 . Most existing bowel preps are based on polyethylene glycol (PEG), an osmotic agent that retains water in the bowel to flush out contents3 . Traditional PEG solutions often require patients to consume large volumes, typically between 2 to 4 liters, which many find difficult to tolerate3 7.
Suflave distinguishes itself by combining PEG with electrolytes such as sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride in a low-volume formulation5 8. This preparation requires patients to consume two doses, each reconstituted with water, followed by additional water intake, but the total volume is significantly less than traditional 4-liter PEG solutions8 9. The low-volume, split-dose regimen is known to enhance patient compliance and improve bowel cleanliness3 7.
In a pivotal head-to-head clinical trial comparing Suflave with the SUPREP Bowel Prep Kit, 94% of patients using Suflave achieved successful bowel cleansing, demonstrating noninferiority6 10. Additionally, the rate of gastrointestinal adverse events was low, with common side effects including nausea, abdominal pain, distension, headache, and vomiting occurring in fewer than 8% of patients8 11.
💡 Did You Know? The FDA has approved Suflave, an osmotic laxative consisting of polyethylene glycol and electrolytes, for colonoscopy preparation in adults. Its lemon-lime sports drink flavor is intended to improve patient tolerance and adherence6 .
The following table summarizes key differences between Suflave and traditional PEG bowel preparations:
| Feature | Suflave | Traditional PEG Solutions |
|---|---|---|
| Active Ingredient | Polyethylene glycol with electrolytes5 | Polyethylene glycol only or with electrolytes3 |
| Volume Required | Low volume; two doses with additional water8 | High volume; often 4 liters3 7 |
| Flavor | Lemon-lime sports drink flavor5 10 | Typically unflavored or unpleasant taste3 |
| Patient Cleansing Success Rate | 94% successful bowel cleansing6 10 | Comparable but with lower tolerability3 |
| Common Adverse Events | Nausea, abdominal pain, headache (<8%) 811 | Similar adverse events but higher volume burden3 |
The low volume and improved formulation of Suflave address major barriers to bowel prep completion, such as taste and volume intolerance3 4. This advancement could lead to higher patient adherence and more effective colonoscopy outcomes.
“Patients frequently struggle with the taste and volume of traditional bowel preparations and fear related to the preparation can also negatively impact patient willingness to undergo follow-up colonoscopy if it is indicated. I believe the palatable lemon-lime flavor of SUFLAVE will be a welcomed option for patients – reducing preparation hesitancy and giving more people the chance to feel comfortable during preparation and getting a successful and effective procedure.”
— Douglas K. Rex, MD, Indiana University School of Medicine10
Improved Prep Taste and Colorectal Cancer Screening
Patient tolerance of bowel preparation remains the largest deterrent to undergoing screening colonoscopy, with 71% of patients citing it as the worst part of the procedure and 55% indicating it as the greatest deterrent to future colonoscopies10 . Poor palatability and the large volume of traditional bowel preps contribute significantly to this hesitancy4 .
Suflave’s lemon-lime sports drink flavor is designed to improve taste acceptability, which is a key factor in patient preference and adherence5 12. In clinical studies, 79% of patients rated Suflave’s taste as neutral to very pleasant compared to 54% for SUPREP, a commonly used bowel prep10 11. Furthermore, 87% found Suflave tolerable or very easy to consume, and 80% reported they would request Suflave for future colonoscopies10 11.
Despite these positive findings, patient reviews indicate some variability in individual experiences. Some patients noted the consistency as thick and the volume still considerable, while others reported effective bowel cleansing with minimal side effects13 . Common adverse events included abdominal pain, distension, nausea, vomiting, and headache, but these were generally mild and infrequent8 11.
Patient adherence to bowel preparation is critical for effective colonoscopy. Suflave’s sports drink flavor and low-volume design address major barriers to completion, potentially improving colorectal cancer screening outcomes5 310.
Improved tolerability through better taste and lower volume is crucial because it directly impacts the quality of bowel cleansing and the likelihood of completing the preparation as instructed3 7. Split-dose and low-volume regimens have been shown to enhance bowel cleanliness and patient compliance, which are essential for detecting precancerous lesions and reducing colorectal cancer mortality3 714.
- Patient barriers to bowel prep completion include:
- Large volume requirements of traditional PEG solutions3 7
- Unpleasant taste and consistency4 13
- Fear and anxiety related to preparation10
- Nausea and gastrointestinal discomfort during prep15 8
- Lack of appealing, safe, and effective low-volume options3 4
Adjunctive measures such as flavored drinks, ice, and anti-nausea medications can help but do not fully resolve adherence challenges15 4. Suflave’s formulation aims to fill this gap by offering a safe, effective, and more palatable option that may increase screening rates and ultimately reduce colorectal cancer deaths5 36.
